These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8974501)

  • 1. [Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].
    Minina LT; Prostakova TM; Meshchano AIu; Kol'tsova GN; Bovenko VN
    Biull Eksp Biol Med; 1996 Sep; 122(9):359-60. PubMed ID: 8974501
    [No Abstract]   [Full Text] [Related]  

  • 2. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 3. Transfusion haemosiderosis and chelation therapy.
    Ley TJ; Griffith P; Nienhuis AW
    Clin Haematol; 1982 Jun; 11(2):437-64. PubMed ID: 7042160
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron chelation in acute iron poisoning and chronic hypersiderosis.
    Walsh JR; Gillick JB
    Clin Pediatr (Phila); 1965 Nov; 4(11):633-8. PubMed ID: 5844429
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic iron overload: new chelators and new strategies.
    Fairbanks VF
    J Lab Clin Med; 1978 Aug; 92(2):141-3. PubMed ID: 681806
    [No Abstract]   [Full Text] [Related]  

  • 6. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone.
    Nielsen P; Fischer R; Engelhardt R; Tondüry P; Gabbe EE; Janka GE
    Br J Haematol; 1995 Dec; 91(4):827-33. PubMed ID: 8547125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the iron chelator desperrioxamine as affected by liposome encapsulation: potential in treatment of chronic hemosiderosis.
    Guilmette RA; Cerny EA; Rahman YE
    Life Sci; 1978 Jan; 22(4):313-20. PubMed ID: 622008
    [No Abstract]   [Full Text] [Related]  

  • 8. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG; Gupta G; Estes WE; Rosenkrantz H; Metterville JJ; Crumbliss AL; Palmer RA; Nordquest KW; Hardy KA; Whitcomb DR; Byers BR; Arceneaux JE; Gaines CG; Sciortino CV
    J Pharmacol Exp Ther; 1979 Jan; 208(1):12-8. PubMed ID: 759605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Iron chelators].
    Villegas A
    Med Clin (Barc); 1994 May; 102(19):739-41. PubMed ID: 8041203
    [No Abstract]   [Full Text] [Related]  

  • 10. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythropoietin versus iron chelators in anaemia and iron overload.
    Vreugdenhil G; van Herpen C; Koene RA
    Neth J Med; 1993 Feb; 42(1-2):45-7. PubMed ID: 8446223
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of chelates for removal of excess iron from the body].
    Meshchanov AIu; Romanova MZh; Kol'tsova GN; Shcherbinina SP
    Gematol Transfuziol; 1989 Mar; 34(3):40-5. PubMed ID: 2656376
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
    Weinberg ED
    J Pharm Pharmacol; 2006 May; 58(5):575-84. PubMed ID: 16640825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of a case of idiopathic pulmonary hemosiderosis treated with an iron chelating agent (desferoxamine B, "Desferal")].
    Poggio GL; Lucioni F
    Minerva Med; 1967 Sep; 58(70):2985-93. PubMed ID: 6054090
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bull's-Eye Maculopathy with Deferoxamine Treatment].
    Schmidt D; Finke J
    Klin Monbl Augenheilkd; 2004 Mar; 221(3):204-9. PubMed ID: 15052528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hemosiderosis and idiopathic hemochromatosis].
    Nowotny P
    Z Gesamte Inn Med; 1967 Dec; 22(24):799-806. PubMed ID: 5585476
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of desferrioxamine B. A new iron eliminating agent, on cases of secondary haemosiderosis in children.
    el-Gholmy A; Khalifa AS; Rahman YA; el-Bagoury I
    J Trop Med Hyg; 1969 Jan; 72(1):22-6. PubMed ID: 5773810
    [No Abstract]   [Full Text] [Related]  

  • 19. [The use of desferrioxamine in iron poisoning and hemosiderosis].
    Karlsson B; Lagercrantz R; Brann I; Strandberg O; Reizenstein P
    Nord Med; 1965 Oct; 74(40):985-8. PubMed ID: 5836665
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experimental research on the use of deferoxamine in the prevention of renal damage from acute ischemia].
    Libra S; Pagano D; Curella G; Litrico V; Cancelliere M; Audibert D; La Terra S; Gruttadauria S; Pappalardo A; D'Alessandro M
    Ann Ital Chir; 1999; 70(4):569-73. PubMed ID: 10573619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.